Pramipexole is a prescription dopamine agonist, a drug that switches on dopamine receptors directly. It was first sold in the US as Mirapex (Boehringer Ingelheim) and is approved for Parkinson’s disease and for moderate-to-severe primary restless legs syndrome (RLS). The brand has been discontinued in the US, but generic immediate-release and extended-release tablets are widely available.
Outside neurology, pramipexole is discussed in bodybuilding circles as an alternative to cabergoline for lowering prolactin, the pituitary hormone that drives milk production. It does lower prolactin in people. However, it is not approved for any prolactin disorder, and no controlled human study has tested it in anabolic steroid users.
This page summarizes what the FDA label, clinical trials and drug-safety studies report. It is for education only and is not medical advice.
| Property | Detail |
|---|---|
| Drug class | Non-ergot dopamine agonist (D2-receptor family, highest affinity for D3) |
| Brands / approval | Mirapex, NDA 020667 (1997); Mirapex ER, NDA 022421 (2010); both brands discontinued, generics marketed |
| Route | Oral tablet, immediate-release (IR) and extended-release (ER) |
| Strengths | IR 0.125–1.5 mg; ER 0.375–4.5 mg |
| Labeled doses | Parkinson’s 1.5–4.5 mg/day; RLS 0.125–0.5 mg once daily, 2–3 h before bedtime |
| Half-life (label) | About 8 h in young healthy adults; about 12 h in older adults |
| Elimination | About 90% of a dose recovered in urine, almost all unchanged |
| Effect on prolactin | Lowers prolactin; not approved for hyperprolactinemia |
| US status | Prescription only; the label lists no DEA controlled-substance schedule |
| WADA | Not named on the 2026 Prohibited List |
What it is
Pramipexole is a small synthetic aminobenzothiazole: formula C₁₀H₁₇N₃S, molecular weight 211.3 g/mol as the free base (PubChem). Tablets contain the dihydrochloride monohydrate salt, molecular weight 302.26 (pramipexole label).
The label describes it as having full agonist activity at the D2 subfamily of dopamine receptors, binding more strongly to D3 than to D2 or D4. In Parkinson’s disease it is thought to work by stimulating dopamine receptors in the striatum, the brain region that loses dopamine input. In the pituitary, dopamine acting on D2 receptors inhibits prolactin release, which is why dopamine agonists lower prolactin (Samuels et al., Br J Clin Pharmacol 2007).
The FDA approved Mirapex tablets in July 1997 and Mirapex ER in February 2010. Drugs@FDA now lists both brands as discontinued; for most Mirapex IR strengths it notes an FDA determination that they were not withdrawn for safety or effectiveness reasons (Drugs@FDA, NDA 020667; Drugs@FDA, NDA 022421).
Pramipexole is often compared with cabergoline, the dopamine agonist actually approved for high prolactin:
| Feature | Pramipexole | Cabergoline |
|---|---|---|
| Chemical class | Non-ergot | Ergot derivative |
| US indication | Parkinson’s disease; RLS | Hyperprolactinemic disorders |
| Half-life | About 8–12 h | 63–69 h (urinary data, 12 healthy subjects) |
| Heart-valve signal in 2007 studies | Not seen | Increased |
Sources for the table: the pramipexole label, the cabergoline label, and the valve studies discussed under side effects below.
Pharmacokinetics
From the immediate-release label:
| Parameter | Value |
|---|---|
| Absolute bioavailability | Over 90% |
| Time to peak (IR) | About 2 h; food delays it by about 1 h without changing total absorption |
| Time to peak (ER) | About 6 h |
| Protein binding | About 15% |
| Volume of distribution | About 500 L |
| Metabolism | Under 10% |
| Elimination | About 90% in urine, almost all as unchanged drug |
| Renal clearance | About 400 mL/min, about 3× the filtration rate (active tubular secretion) |
| Half-life | About 8 h (young adults); about 12 h (elderly) |
| Steady state | Within 2 days (IR); within 5 days (ER) |
Because the kidneys clear almost all of the drug, kidney function drives exposure. Clearance was about 60% lower with moderate renal impairment (creatinine clearance ≈ 40 mL/min) and about 75% lower with severe impairment (≈ 20 mL/min). The label therefore uses smaller and less frequent doses in kidney disease. Clearance is also about 30% lower in people over 65, which explains the longer half-life in older adults.
The extended-release tablet is taken once daily. In healthy volunteers, 4.5 mg ER once daily matched 1.5 mg IR three times daily for peak level and 24-hour exposure (ER label).
Approved medical use
Parkinson’s disease
The IR label starts at 0.375 mg/day in three divided doses and raises the dose no more often than every 5–7 days:
| Week | Dose | Total daily dose |
|---|---|---|
| 1 | 0.125 mg three times daily | 0.375 mg |
| 2 | 0.25 mg three times daily | 0.75 mg |
| 3 | 0.5 mg three times daily | 1.5 mg |
| 4 | 0.75 mg three times daily | 2.25 mg |
| 5 | 1 mg three times daily | 3.0 mg |
| 6 | 1.25 mg three times daily | 3.75 mg |
| 7 | 1.5 mg three times daily | 4.5 mg |
The labeled maintenance range is 1.5–4.5 mg/day. In a fixed-dose study, 3, 4.5 and 6 mg/day gave no significant benefit beyond 1.5 mg/day, while several side effects rose with dose. The ER tablet starts at 0.375 mg once daily, up to a maximum of 4.5 mg/day.
When stopping, the label tapers by 0.75 mg/day until the dose reaches 0.75 mg/day, then by 0.375 mg/day. This is to reduce the risk of a reaction resembling neuroleptic malignant syndrome (fever, rigidity, confusion).
Restless legs syndrome
For RLS, only the IR tablet is labeled. The dose is 0.125 mg once daily, 2–3 hours before bedtime, increased every 4–7 days if needed to 0.25 mg and then 0.5 mg. Some patients received 0.75 mg in open-label use, but the label states there is no evidence it adds benefit over 0.5 mg.
What the research shows
Parkinson’s disease
The label summarizes the key placebo-controlled trials. The UPDRS is the standard Parkinson’s rating scale: part II covers daily activities (worst score 52) and part III covers motor signs (worst score 108).
| Trial | n | Design | Pramipexole | Placebo |
|---|---|---|---|---|
| Early PD, flexible dose | 335 | 7-week titration, 6-month maintenance, up to 4.5 mg/day | UPDRS II −1.9; III −5.0 | UPDRS II +0.4; III +0.8 |
| Early PD, fixed dose | 264 | 1.5, 3, 4.5 or 6 mg/day; 4-week maintenance | UPDRS II −1.8; III −4.2 | UPDRS II −0.3; III −0.6 |
| Advanced PD, on levodopa | 360 | 7-week titration, 6-month maintenance | UPDRS II −2.7; III −5.6; “off” time 6 → 4 h/day | UPDRS II −0.5; III −2.8; “off” time stayed at 6 h/day |
Negative numbers are improvements. All differences were statistically significant. The fixed-dose trial showed no dose response, and in the advanced trial levodopa doses were cut by an average of 27%.
Restless legs syndrome
In a 12-week fixed-dose trial of 344 patients, all three doses beat placebo on the 0–40 International RLS (IRLS) rating scale and on clinician-rated global improvement:
| Arm | n | IRLS change | Much or very much improved |
|---|---|---|---|
| 0.25 mg | 88 | −13.1 | 74.7% |
| 0.5 mg | 79 | −13.4 | 67.9% |
| 0.75 mg | 87 | −14.4 | 72.9% |
| Placebo | 85 | −9.4 | 51.2% |
There was no clear dose response across the three doses.
Prolactin lowering in humans
Pramipexole’s effect on prolactin is well documented, but only in short studies of healthy volunteers:
- Single low doses. In a randomized, double-blind crossover study in 12 healthy volunteers, single doses of 0.1, 0.2 and 0.3 mg lowered prolactin in a dose-dependent way, with the largest effect 2–4 hours after dosing. Growth hormone rose briefly (Schilling et al., Clin Pharmacol Ther 1992).
- 0.5 mg single dose. Two double-blind, placebo-controlled studies in 16 healthy men each found that 0.5 mg lowered prolactin and raised growth hormone. It also reduced alertness (Samuels et al., J Psychopharmacol 2006; Samuels et al., Br J Clin Pharmacol 2007).
The label adds that pramipexole “inhibits secretion of prolactin in humans,” so it is expected to suppress breast-milk production. In rats, the drop in prolactin disrupted implantation and early pregnancy.
These studies show the direction of the effect, not a treatment. No randomized trial has tested pramipexole for hyperprolactinemia or prolactin-secreting pituitary tumors. The human evidence for that use is limited to case reports, such as one man with schizophrenia whose risperidone-related high prolactin and sexual dysfunction were treated with low-dose pramipexole (Ishitobi et al., J Clin Psychopharmacol 2011). The US-approved dopamine agonist for these conditions is cabergoline.
Treatment-resistant depression (investigational)
The PAX-D trial randomized 151 adults with depression that had not responded to antidepressants to pramipexole (titrated to 2.5 mg/day) or placebo, added to their existing antidepressant (Browning et al., Lancet Psychiatry 2025):
| Outcome at week 12 | Pramipexole | Placebo |
|---|---|---|
| Fall in QIDS-SR16 depression score (from ≈ 16) | 6.4 points | 2.4 points |
| Difference between groups | −3.91 (95% CI −5.37 to −2.45) | — |
| Stopped treatment due to adverse events | 20% | 5% |
The most common side effects were nausea, headache, and sleep disturbance or sleepiness. Depression is not an approved indication.
Sexual function and use alongside anabolic steroids
About pramipexole as a “prolactin” or “gyno” drug. Pramipexole is sometimes recommended online for users of nandrolone or trenbolone, either to control prolactin or to improve libido and erections. We found no controlled human study of pramipexole in anabolic steroid users, for gynecomastia, or for sexual function in healthy men. Pramipexole is not a SERM and does not block estrogen.
What the evidence does show:
- Animal data. In rats and mice, D3-preferring agonists including pramipexole induce penile erection and yawning, effects blocked by a D3 antagonist (Collins et al., J Pharmacol Exp Ther 2009). These are animal results and do not show a benefit in people.
- Label data in patients. In early Parkinson’s trials, impotence was reported in 2% on pramipexole vs 1% on placebo, and decreased libido in 1% vs 0%.
- Hypersexuality. Compulsive sexual behavior is a recognized impulse-control side effect (see below), which is a harm, not a therapeutic effect.
- Prolactin in steroid users. One cross-sectional study of 60 gym-goers in Baghdad found higher prolactin in the 30 anabolic steroid users than in 30 non-users (Qasim Ali et al., Steroids 2024). It could not show which drug was responsible or whether the rise caused symptoms.
Side effects and risks
Pramipexole has no boxed warning and no listed contraindications. Its warnings section is long, however, and several of the risks are serious.
Falling asleep without warning
Patients on pramipexole have fallen asleep during daily activities, including driving, sometimes causing accidents. Some reported no drowsiness beforehand, and some events occurred as late as a year after starting. Somnolence is common at Parkinson’s doses above 1.5 mg/day. In RLS trials at 0.25–0.75 mg/day it occurred in 6% vs 3% on placebo. Sedating drugs, alcohol and drugs that raise pramipexole levels add to the risk.
Impulse control disorders
Dopamine agonists can cause compulsive gambling, hypersexuality, compulsive buying and binge eating. People often do not recognize the behavior as a drug effect.
| Study | Design | Finding |
|---|---|---|
| Weintraub et al., Arch Neurol 2010 | 3,090 Parkinson’s patients, 46 centers | Any impulse-control disorder in 17.1% on a dopamine agonist vs 6.9% not on one (OR 2.72, 95% CI 2.08–3.54); pramipexole 17.7% vs ropinirole 15.5% (not significantly different) |
| Bostwick et al., Mayo Clin Proc 2009 | 267 Parkinson’s patients, records review | New gambling or hypersexuality in 7 of 38 (18.4%) on therapeutic agonist doses (≥ 2 mg/day pramipexole or ≥ 6 mg/day ropinirole); none on levodopa alone |
| Moore et al., JAMA Intern Med 2014 | FDA adverse event reports, 2003–2012 | Strongest signal among the dopamine agonists was for pramipexole: 410 reports, proportional reporting ratio 455.9 |
In the Mayo series, the behaviors eased after the agonist was stopped or reduced. The label advises asking patients directly about new urges and considering dose reduction or discontinuation.
Hallucinations and psychosis
In the label’s placebo-controlled trials, hallucinations occurred in:
- 9% vs 2.6% on placebo in early Parkinson’s disease;
- 16.5% vs 3.8% in advanced disease (with levodopa);
- 1 of 889 patients in the RLS program.
Risk rose with age. The label states that people with a major psychotic disorder should ordinarily not be treated with dopamine agonists.
Common side effects
From the pooled RLS trials (575 patients on 0.125–0.75 mg/day vs 223 on placebo, up to 12 weeks):
| Side effect | Pramipexole | Placebo |
|---|---|---|
| Nausea | 16% | 5% |
| Headache | 16% | 15% |
| Fatigue | 9% | 7% |
| Somnolence | 6% | 3% |
| Constipation | 4% | 1% |
| Dry mouth | 3% | 1% |
Nausea was dose-related: 11% at 0.25 mg, 19% at 0.5 mg and 27% at 0.75 mg, vs 5% on placebo. In early Parkinson’s disease at higher doses, nausea (28% vs 18%), somnolence (22% vs 9%), insomnia (17% vs 12%) and constipation (14% vs 6%) were the most frequent.
Blood pressure and heart rate
Dopamine agonists can cause orthostatic hypotension (a drop in blood pressure on standing), especially while the dose is being raised. In a study of 60 healthy volunteers titrated faster than the label allows, supine blood pressure and pulse instead rose by about 10/7 mmHg and 10 beats/min over placebo.
Heart valves and fibrosis
The valve damage linked to ergot-derived agonists such as cabergoline has not been shown for pramipexole:
- In an echocardiography study, moderate-to-severe valve regurgitation was found in 28.6% of cabergoline users, 0% of 42 patients on non-ergot agonists, and 5.6% of controls (Zanettini et al., NEJM 2007).
- In a UK case-control study, valve regurgitation was increased with pergolide and cabergoline but not with other dopamine agonists (Schade et al., NEJM 2007).
The label still notes postmarketing reports of possible peritoneal, pleural and pulmonary fibrosis with pramipexole, without proof of cause.
Stopping the drug: withdrawal, rebound and augmentation
- Withdrawal symptoms. Apathy, anxiety, depression, fatigue, insomnia, sweating and pain have been reported during taper or after stopping. They generally do not respond to levodopa.
- RLS rebound. In a 26-week trial, symptoms worsened beyond baseline after abrupt withdrawal in 10% vs 2% on placebo.
- RLS augmentation (symptoms starting earlier in the day, becoming stronger and spreading) was reported in 12% vs 9% on placebo, and rose with longer exposure.
Retina (animal data)
In albino rats, two years of pramipexole caused degeneration of light-sensing retinal cells. This was not seen in pigmented rats, mice, monkeys or minipigs. A two-year human study comparing pramipexole with ropinirole found no difference between drugs, but it had no placebo group and could only detect large differences.
Interactions
- Dopamine blockers such as antipsychotics and metoclopramide may reduce pramipexole’s effect.
- Cimetidine raised pramipexole exposure (AUC) by 50% and its half-life by 40%, by blocking its secretion in the kidney.
- Other drugs secreted by the same kidney pathway (for example ranitidine, diltiazem, verapamil, quinidine) lowered pramipexole clearance by about 20% in population analyses.
- Levodopa: pramipexole raised peak levodopa levels by about 40%.
Pregnancy and breastfeeding
There are no adequate human pregnancy data. In rats, pramipexole caused embryo loss, thought to reflect prolactin suppression (rats need prolactin for early pregnancy; humans do not), and slowed offspring growth. Milk production is expected to fall.
Legal status and use outside medicine
In the US, pramipexole is a prescription drug. Its label lists no DEA schedule, and it is not named on the WADA 2026 Prohibited List. Product obtained outside the regulated pharmacy supply is not subject to FDA quality controls for identity or dose.
Key takeaways
- An approved neurology drug. Pramipexole is a non-ergot dopamine agonist approved for Parkinson’s disease and restless legs syndrome, now sold in the US only as generics.
- It lowers prolactin, but that is not an approved use. Healthy-volunteer studies confirm the effect. No trial has tested it for high prolactin, gynecomastia or anabolic steroid users; cabergoline is the approved prolactin drug.
- Short, kidney-dependent half-life. About 8 hours in young adults and 12 in older adults, with almost all of the drug excreted unchanged in urine.
- Sleep attacks and impulse-control disorders are the key risks. About 1 in 6 Parkinson’s patients on a dopamine agonist had an impulse-control disorder in the largest survey, and pramipexole had the strongest signal among dopamine agonists in FDA adverse-event reports.
- No heart-valve signal like cabergoline’s. Large 2007 studies linked valve damage to ergot agonists, not to non-ergot drugs such as pramipexole.
- Stopping needs care. The label calls for a taper, and withdrawal, rebound and RLS augmentation are documented.
Sources
- Torrent Pharmaceuticals. Pramipexole dihydrochloride tablets, prescribing information (revised 2026). DailyMed.
- Ingenus Pharmaceuticals. Pramipexole dihydrochloride extended-release tablets, prescribing information (revised 2025). DailyMed.
- Food and Drug Administration. Drugs@FDA: Mirapex (pramipexole dihydrochloride), NDA 020667. FDA.
- Food and Drug Administration. Drugs@FDA: Mirapex ER (pramipexole dihydrochloride), NDA 022421. FDA.
- National Center for Biotechnology Information. Pramipexole, PubChem CID 119570. PubChem.
- Teva Pharmaceuticals USA. Cabergoline tablets, prescribing information. DailyMed.
- Schilling JC, Adamus WS, Palluk R. Neuroendocrine and side effect profile of pramipexole, a new dopamine receptor agonist, in humans. Clin Pharmacol Ther. 1992;51(5):541–548. PubMed.
- Samuels ER, Hou RH, Langley RW, et al. Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers. J Psychopharmacol. 2006;20(6):756–770. PubMed.
- Samuels ER, Hou RH, Langley RW, et al. Comparison of pramipexole with and without domperidone co-administration on alertness, autonomic, and endocrine functions in healthy volunteers. Br J Clin Pharmacol. 2007;64(5):591–602. PubMed.
- Ishitobi M, Kosaka H, Shukunami K, et al. Adjunctive treatment with low-dosage pramipexole for risperidone-associated hyperprolactinemia and sexual dysfunction in a male patient with schizophrenia. J Clin Psychopharmacol. 2011;31(2):243–245. PubMed.
- Browning M, Cowen PJ, Galal U, et al. Pramipexole augmentation for the acute phase of treatment-resistant, unipolar depression: a placebo-controlled, double-blind, randomised trial in the UK. Lancet Psychiatry. 2025;12(8):579–589. PubMed.
- Collins GT, Truccone A, Haji-Abdi F, et al. Proerectile effects of dopamine D2-like agonists are mediated by the D3 receptor in rats and mice. J Pharmacol Exp Ther. 2009;329(1):210–217. PubMed.
- Qasim Ali L, Alshammary RAA, Ghazi Alshammary A, Jouda J. A hormonal side effect of anabolic steroids among a sample of Baghdad male bodybuilders. Steroids. 2024;209:109465. PubMed.
- Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010;67(5):589–595. PubMed.
- Bostwick JM, Hecksel KA, Stevens SR, et al. Frequency of new-onset pathologic compulsive gambling or hypersexuality after drug treatment of idiopathic Parkinson disease. Mayo Clin Proc. 2009;84(4):310–316. PubMed.
- Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med. 2014;174(12):1930–1933. PubMed.
- Zanettini R, Antonini A, Gatto G, et al. Valvular heart disease and the use of dopamine agonists for Parkinson’s disease. N Engl J Med. 2007;356(1):39–46. PubMed.
- Schade R, Andersohn F, Suissa S, et al. Dopamine agonists and the risk of cardiac-valve regurgitation. N Engl J Med. 2007;356(1):29–38. PubMed.
- World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA 2026 Prohibited List.